Market Overview

Noble Financial Initiates Heron Therapeutics At Buy

Brean Capital Sees A $300 Million Opportunity For Heron Therapeutics New Drug Launch
FDA Approval Of Heron Therapeutics' Lead Product Has Lake Street Recommending A Buy

Noble Financial initiated coverage on shares of Heron Therapeutics (NASDAQ: HRTX) with a Buy rating.

The target price for Heron Therapeutics is set to $18.

Heron Therapeutics shares have declined 8.26% over the past 52 weeks, while the S&P 500 index has gained 13.56% in the same period.

Heron Therapeutics' shares dropped 1.17% to close at $8.44 yesterday.

Latest Ratings for HRTX

Oct 2016Brean CapitalAssumesBuy
Oct 2016JefferiesMaintainsBuy
Sep 2016Lake StreetAssumesBuy

View More Analyst Ratings for HRTX
View the Latest Analyst Ratings

Posted-In: Noble FinancialInitiation Analyst Ratings


Related Articles (HRTX)

View Comments and Join the Discussion!